oalib
Search Results: 1 - 10 of 100 matches for " "
All listed articles are free for downloading (OA Articles)
Page 1 /100
Display every page Item
Glioblastoma Multiforme—Treating a Deadly Tumor with Both Strands of RNA  [PDF]
Robert J Weil
PLOS Medicine , 2006, DOI: 10.1371/journal.pmed.0030031
Abstract:
Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields  [cached]
Rulseh Aaron,Keller Ji?í,Klener Jan,?roubek Jan
World Journal of Surgical Oncology , 2012, DOI: 10.1186/1477-7819-10-220
Abstract: Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor, and has a median survival of only 10 to 14 months with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median survival to only five to seven months with optimal therapy. Tumor-treating fields (TTField) therapy is a novel treatment technique that has recently received CE and FDA approval for the treatment of RGBM, and is based on the principle that low intensity, intermediate frequency electric fields (100 to 300 kHz) may induce apoptosis in specific cell types. Our center was the first to apply TTField treatment to histologically proven GBM in a small pilot study of 20 individuals in 2004 and 2005, and four of those original 20 patients are still alive today. We report two cases of GBM and two cases of RGBM treated by TTField therapy, all in good health and no longer receiving any treatment more than seven years after initiating TTField therapy, with no clinical or radiological evidence of recurrence.
Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound
Yang FY, Teng MC, Lu M, Liang HF, Lee YR, Yen CC, Liang ML, Wong TT
International Journal of Nanomedicine , 2012, DOI: http://dx.doi.org/10.2147/IJN.S29229
Abstract: eating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound Original Research (3162) Total Article Views Authors: Yang FY, Teng MC, Lu M, Liang HF, Lee YR, Yen CC, Liang ML, Wong TT Published Date February 2012 Volume 2012:7 Pages 965 - 974 DOI: http://dx.doi.org/10.2147/IJN.S29229 Received: 15 December 2011 Accepted: 06 January 2012 Published: 21 February 2012 Feng-Yi Yang1, Ming-Che Teng1, Maggie Lu2, Hsiang-Fa Liang2, Yan-Ru Lee1, Chueh-Chuan Yen3, Muh-Lii Liang4,5, Tai-Tong Wong5 1Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, 2Drug Delivery Laboratory, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 3Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, 4Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, 5Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan Background: High-dose tissue-specific delivery of therapeutic agents would be a valuable clinical strategy. We have previously shown that repeated transcranial focused ultrasound is able to increase the delivery of Evans blue significantly into brain tissue. The present study shows that repeated pulsed high-intensity focused ultrasound (HIFU) can be used to deliver high-dose atherosclerotic plaque-specific peptide-1 (AP-1)-conjugated liposomes selectively to brain tumors. Methods: Firefly luciferase (Fluc)-labeled human GBM8401 glioma cells were implanted into NOD-scid mice. AP-1-conjugated liposomal doxorubicin or liposomal doxorubicin alone was administered followed by pulsed HIFU and the doxorubicin concentration in the treated brains quantified by fluorometer. Growth of the labeled glioma cells was monitored through noninvasive bioluminescence imaging and finally the brain tissue was histologically examined after sacrifice. Results: Compared with the control group, the animals treated with 5 mg/kg injections of AP-1 liposomal doxorubicin or untargeted liposomal doxorubicin followed by repeated pulsed HIFU not only showed significantly enhanced accumulation of drug at the sonicated tumor site but also a significantly elevated tumor-to-normal brain drug ratio (P < 0.001). Combining repeated pulsed HIFU with AP-1 liposomal doxorubicin or untargeted liposomal doxorubicin has similar antitumor effects. Conclusion: This study demonstrates that targeted or untargeted liposomal doxorubicin, followed by repeated pulsed HIFU, is a promising high-dose chemotherapy method that allows the desired brain tumor region to be targeted specifically.
Exploiting the inherent invasive property totreat glioblastoma multiforme
-
 [PDF]

ZHANG Feng,LIAO Heng
- , 2015,
Abstract: Glioblastoma multiforme (GBM) is the most malignant brain tumor with high infiltration. The routinesurgical resection followed by radiation and chemotherapy only provides patients with a survival period ranging 12–15months. Here, I propose that the high invasiveness property of the GBM cells be exploited to treat this deadly disease. Thatis, instead of inhibiting the dissemination of GBM cells, we should take advantage of the high mobility of the disseminatedGBM cells and directionally induce these cells to return to the center of surgical resection cavity of the primary neoplasmand subsequently kill them. This idea may provide a new promise to defeat this deadly disease.
Glioblastoma multiforme y embarazo Glioblastoma multiforme and pregnancy  [cached]
Martha C Trujillo C,Salim S Barhoum F,Héctor J Meléndez F
Revista Colombiana de Anestesiología , 2012,
Abstract: Reportamos el caso de una paciente de 27 a os de edad, G2P1, a quien se le diagnostica en la semana 20 de gestación un tumor supratentorial frontal izquierdo tipo glioblastoma multiforme, el cual se manifestó con una crisis de ausencia. La conducta tomada fue quirúrgica y la paciente fue sometida en la semana 28 a craneotomía bajo anestesia general, con monitoreo fetal, con resultados exitosos para la madre y el feto. Dado lo infrecuente de esta asociación, creemos importante su reporte. This is a case report of a 27-year-old female patient, G2P1, diagnosed at 20 weeks of gestation with a left frontal supratentorial tumor of a glioblastoma multiforme type, which manifested in the form of ictal absence. The patient was taken to surgery on week 28 and underwent a craniotomy under general anesthesia and fetal monitoring, with a successful outcome for both the mother and the fetus. We consider it important to report this case given this rare association.
Current management of glioblastoma multiforme
Moscote-Salazar Luís Rafael,Meneses-García Carlos,Sáenz-Amuruz Miguel,Penagos Pedro
Revista Ciencias Biomédicas , 2010,
Abstract: The glioblastoma multiforme is a agressive tumor in the brain. Despite aggressive multimodal treatment including surgical excision, local and systemic chemotherapy, median survival is in the range of 12 months. Patients with glioblastoma multiforme are considered to receive only palliative treatment with no hope of cure. Surgical resection is based on the premise that provides themaximum possible lengthen survival but with lower neurological deficit. Radiation therapy increases the duration of survival but is not curative and chemotherapeutic agents such as carmustine-based meta-analysis provide a discreet increase in survival but its use has not been widespread. We present a review of the current management of glioblastoma multiforme to the staff of Health SciencesRESUMENEl glioblastoma multiforme es el más común y más agresivo tumor del sistema nervioso central y se asocia con la mas baja sobrevida de todos los canceres en humanos. A pesar del tratamiento agresivo multimodal que comprende la resección quirúrgica, quimioterapia local y sistémica, la sobrevida media está en el rango de los 12 meses. Los pacientes con glioblastomas multiformes son considerados a recibir únicamente tratamiento de carácter paliativo sin ninguna esperanza de curación. La resección quirúrgica se basa en la premisa de la máxima posible que provea y alargue la sobrevida pero con el menor déficit neurológico. La radioterapia incrementa la duración de la sobrevida pero no es curativa y los agentes quimioterapéuticos como la carmustina ofrecen, basado en metanálisis, un discreto incremento en la sobrevida pero su uso todavía no se ha generalizado. Presentamos una revisión del estado actual del manejo del glioblastoma multiforme para el personal de ciencias de la salud
Massively Parallel Signature Sequencing and Bioinformatics Analysis Identifies Up-Regulation of TGFBI and SOX4 in Human Glioblastoma  [PDF]
Biaoyang Lin,Anup Madan,Jae-Geun Yoon,Xuefeng Fang,Xiaowei Yan,Taek-Kyun Kim,Daehee Hwang,Leroy Hood,Gregory Foltz
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0010210
Abstract: A comprehensive network-based understanding of molecular pathways abnormally altered in glioblastoma multiforme (GBM) is essential for developing effective therapeutic approaches for this deadly disease.
Morphology Of Cultured Cells Of Glioblastoma Multiforme  [PDF]
Ramazan DURMAZ
Journal of Neurological Sciences , 2007,
Abstract: The aim of the present study is to asses the morphology of cultured glioblastoma multiforme cells obtained from five patients. Established tissue cultures of malignant astrocytoma cells showed polymorphic characters phenotypically. There were various types of tumor cells including ovoid cytoplasm with multiple processes, elongated unipolar and bipolar, spindle, bizarre in shape, and large flat cell as well as multinucleated gigantic form. As the passage of the tissue culture of glioblastoma multiforme continued, their cell morphology became more similar in appearance. In the present study, the glioblastoma multiforme cells in vitro included heterogeneous subpopulations of tumor cells, which may explain why the treatment modalities remain insufficient in clinics.
Cerebellar glioblastoma multiforme in an adult
Mattos, Jo?o Paulo;Marenco, Horacio Armando;Campos, José Maria;Faria, Andréa Vasconcellos;Queiroz, Luciano Souza;Borges, Guilherme;Oliveira, Evandro de;
Arquivos de Neuro-Psiquiatria , 2006, DOI: 10.1590/S0004-282X2006000100028
Abstract: cerebellar glioblastoma multiforme (gbm) is a rare tumor. this is the third case published in brazilian literature and, the last one has been described more than 15 years ago. the aggressive behavior of gbm prompts for fast treatment, which can be hampered by the fact that the diagnosis of gbm requires a high degree of suspicion. we describe a case of gbm in a 46 years old man. in conjunction, we present a literature review including particular issues, clinical data, advances in imaging studies, pathological characteristics, treatment options and the behavior of such malignant tumor.
Cerebellar glioblastoma multiforme in an adult  [cached]
Mattos Jo?o Paulo,Marenco Horacio Armando,Campos José Maria,Faria Andréa Vasconcellos
Arquivos de Neuro-Psiquiatria , 2006,
Abstract: Cerebellar glioblastoma multiforme (GBM) is a rare tumor. This is the third case published in Brazilian literature and, the last one has been described more than 15 years ago. The aggressive behavior of GBM prompts for fast treatment, which can be hampered by the fact that the diagnosis of GBM requires a high degree of suspicion. We describe a case of GBM in a 46 years old man. In conjunction, we present a literature review including particular issues, clinical data, advances in imaging studies, pathological characteristics, treatment options and the behavior of such malignant tumor.
Page 1 /100
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.